Re: Confidentiality AgreementNovo Nordisk a S • November 24th, 2021 • Pharmaceutical preparations
Novo Nordisk (referred to herein as “you or your”) has requested certain Evaluation Material (as defined below) from Dicerna Pharmaceuticals, Inc. (together with its subsidiaries, the “Company”) in connection with the evaluation, negotiation or completion of a potential negotiated transaction between you and the Company (the “Potential Transaction”). You and the Company are each individually referred to in this agreement (this “Agreement”) individually as a “Party” and, collectively, as the “Parties.”
MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • November 24th, 2021 • Novo Nordisk a S • Pharmaceutical preparations • England
AMENDMENTNovo Nordisk a S • November 24th, 2021 • Pharmaceutical preparations
CONFIDENTIAL DISCLOSURE AGREEMENTConfidential Disclosure Agreement • November 24th, 2021 • Novo Nordisk a S • Pharmaceutical preparations • Delaware
THIS CONFIDENTIAL DISCLOSURE AGREEMENT (the “Agreement”) is made as of the last dated signature below (the “Effective Date”) by and between Dicerna Pharmaceuticals Inc., a Delaware corporation with a business address at 33 Hayden Avenue, Lexington, Massachusetts 02421 (Tel: 617-621-8097; Fax: 6l7-252-0976)(“Dicerna”), and Novo Nordisk A/S, with a business address at Novo Alle I, 2880 Bagsvaerd, Denmark (“COMPANY”) (each a “Party” and, collectively, the “Parties”).
